Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26189038 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Isaac Micallef und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japa…. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Enzyme Inhibitors, Neoplasms, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Standard cancer chemotherapy is increasingly being supplemented with novel therapeutics to overcome known chemoresistance pathways. Resistance to treatment is common across various tumour types, driven by multiple mechanisms. One emerging contributor is protein methylation, a post-translational modification mediated by protein methyltransferases (PMTs), which regulate protein function by adding methyl groups, mainly on lysine and arginine residues. Dysregulation of protein lysine methyltransferases (PKMTs) and protein arginine methyltransferases (PRMTs) has been linked to cancer progression and drug resistance, making them attractive therapeutic targets. Consequently, several small-molecule PMT inhibitors have been developed, with some progressing to clinical trials. However, many candidates showing promise in preclinical studies fail to demonstrate efficacy or safety in later stages, limiting clinical success. This gap highlights the need to rethink current approaches to PMT inhibitor design. A deeper understanding of PMT mechanisms, catalytic domains, and their roles in chemoresistance is essential for creating more selective, potent, and clinically viable inhibitors. This review will summarise major chemoresistance pathways and PMTs implicated in cancer, then explore current and prospective PMT inhibitor classes. Building on mechanistic insights, we propose strategies to develop next-generation inhibitors with improved therapeutic potential against chemoresistant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
- Centre for Molecular Medicine and Biobanking, University of Malta, MSD 2080 Msida, Malta.
ORCID-Profile: Isaac Micallef, Byron Baron
Zitieren
APA
Micallef, I., & Baron, B. (2025). Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26189038
Vancouver
Micallef I, Baron B. Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26189038
BibTeX
@article{Micallef2025,
author = {Micallef, Isaac and Baron, Byron},
title = {Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26189038}
}
EUVIMED